Latest Content

10 of 2244 Shown
  • Strategic ART Switching: If It’s Not Broken, Should We Still Fix It?

    David A. Wohl MD - 5/27/2015
    How do the DHHS guidelines and recent switch studies affect our decision to change regimens in virologically suppressed patients?
  • Will Healthcare Reform Challenge Our Ability to Prescribe Single-Tablet Regimens?

    William G. Powderly MD - 5/18/2015
    I recently encountered an unexpected challenge in my clinic after prescribing a single-tablet regimen for a newly diagnosed HIV-infected patient.
  • My Take on the Latest DHHS Guidelines: The Increasing Role for Integrase Inhibitors in First-line Therapy

    Daniel R. Kuritzkes MD - 5/15/2015
    With the latest update to the DHHS guidelines for ART, chances are you will be starting most patients on an integrase inhibitor–based regimen.
  • Analyzing NA-ACCORD: Should You Avoid Abacavir In Patients With Cardiovascular Risk?

    Josep M. Llibre MD - 5/15/2015 1 comment / Last Comment: 5/19/2015
    The recent NA-ACCORD data presented at CROI 2015 has reignited discussion on the potential association between abacavir exposure and MI. But there are several limitations of this analysis to consider before altering your practice.
  • Using Archived HIV-1 DNA Resistance Testing When Considering Switching: What Are the Limitations?

    Charles B. Hicks MD - 5/1/2015 1 comment / Last Comment: 5/19/2015
    As the enthusiasm for switching virologically suppressive ART regimens to simpler treatment options grows, one major concern is ensuring that the simpler regimen can maintain virologic suppression when unrecognized HIV drug resistance may be present in archived viruses.
  • Considerations on the Use of Fixed-Dosed Combination Therapy in a Patient With Multiple Comorbidities

    Eric S. Daar MD - 4/21/2015 1 comment / Last Comment: 5/19/2015
    In this case-based example, I describe the available options for single-tablet ART regimens in a patient with CVD risk factors and renal disease, including how recent data influence the management strategy.
  • Learning Module cme-icon

    Clinical Impact of Data From the 2015 Conference on Retroviruses and Opportunistic Infections

    Joseph J. Eron, Jr., MD; Joel E. Gallant, MD, MPH; and Kathleen E. Squires, MD, guide participants through interpretation of key studies from this important annual conference and applying results to clinical practice.
    Faculty: Joseph J. Eron, Jr. MD, Joel E. Gallant MD, MPH, Kathleen E. Squires MD
    Released: 4/17/2015
  • How I Decided Whether to Stop a Potentially Inactive NRTI in a Patient Receiving a Suppressive Regimen

    Renslow Sherer MD - 4/17/2015 1 comment / Last Comment: 4/24/2015
    How does the risk of ongoing NRTI-related toxicity in a patient weigh up against the limited antiviral contribution to a suppressive regimen? The data that informed my decision.
  • Lessons Learned in the Clinic: Why a Complete Treatment History Is Essential Information for Treatment Simplification

    Joseph J. Eron, Jr. MD - 4/7/2015 3 comments / Last Comment: 5/18/2015
    A recent seemingly straightforward case of treatment simplification took an interesting turn about 10 months after switching therapy.
  • The Availability of Coformulated Cobicistat-Boosted Protease Inhibitors and the Impact on My Practice

    David A. Wohl MD - 3/18/2015 3 comments / Last Comment: 4/24/2015
    In both treatment-naive and virologically suppressed patients, the availability of fixed-dose cobicistat-boosted PIs makes me take another look at my management approach.
10 of 2244 Shown
Show 10 More
Decision Support
Immediate answers to treatment questions
More than just up to date